1
|
Assessment of Psoriatic Skin Features Using Non-Invasive Imaging Technique. Processes (Basel) 2022. [DOI: 10.3390/pr10050985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/10/2022] Open
Abstract
Background: Psoriasis is one of the most commonly recognized dermatological diseases, characterized by distinct structural changes, hyperproliferation and inflammation. The aim of the study was quantitative comparisons of psoriatic skin with skin without psoriatic lesions by non-invasive imaging methods. Methods: 71 patients diagnosed with psoriasis vulgaris underwent non-invasive imaging of skin at the site of the psoriatic lesion and at the site without such lesion. Skin density, epidermis thickness and subepidermal low-echogenic band (SLEB) thickness were measured by high-resolution ultrasound (HFU). Blood perfusion was assessed using laser speckle contrast analysis (LASCA) and skin temperature was measured by thermal imaging camera. Hyperspectral camera was used to obtain spectral reflectance profiles in psoriatic lesion and skin without psoriatic changes. Results: The greatest differences in skin density and epidermal thickness between psoriatic and unchanged skin were observed on the forearms. The skin covered with psoriatic plaques was 80% less dense, and the epidermis in this area was 121% thicker. The greatest thickness of SLEB was observed in the knee area (Me = 0.389 mm). Skin with psoriatic lesions is characterized by a higher temperature (Me = 33.6 vs. Me = 31) and blood perfusion than skin without psoriasis (Me = 98.76 vs. Me = 50.65). Skin without psoriasis shows lower reflectance than psoriatic lesion from 623 nm to 1000 nm; below this value, skin without psoriatic lesion shows higher reflectance. Conclusions: Skin density and epidermis thickness, skin blood perfusion, temperature and reflectance can be useful parameters for monitoring the course of psoriasis and its treatment, especially since the examination of psoriatic skin with proposed methods is non-invasive, quantitative and easy to perform in clinical conditions.
Collapse
|
2
|
Trohman RG. My Double Trouble: An Autobiographical Case Report of Psoriasis and Psoriatic Arthritis. Cureus 2021; 13:e20617. [PMID: 34956807 PMCID: PMC8694657 DOI: 10.7759/cureus.20617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/21/2021] [Indexed: 11/23/2022] Open
Abstract
Psoriasis and psoriatic arthritis are overlapping, related, but distinct entities. Each occurs as a result of a complex combination of precipitants, genetic predispositions, and variable expression of a self-sustaining proinflammatory state. My case history and clinical course are outlined below. In addition, the epidemiology, pathogenesis, and the expanding armamentarium of treatment options, including their strengths and weaknesses, are discussed in detail.
Collapse
Affiliation(s)
- Richard G Trohman
- Cardiac Electrophysiology, Rush University Medical Center, Chicago, USA
| |
Collapse
|
3
|
Monsour EP, Pothen J, Balaraman R. A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report. Cureus 2019; 11:e5824. [PMID: 31754559 PMCID: PMC6827694 DOI: 10.7759/cureus.5824] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
While immune checkpoint inhibitors have been groundbreaking for cancer treatment, there are many reported cases of patients undergoing immunotherapy who have discontinued or temporarily interrupted treatment due to the development of autoimmune-related adverse effects. Here, we present a 63-year-old female with a history of psoriasis (in spontaneous remission) and newly diagnosed poorly differentiated lung adenocarcinoma (pTXN3M1a) who experienced a severe flare-up of her psoriasis three months after initiating single-agent pembrolizumab. The patient was initially treated with topical clobetasol propionate ointment, however, due to minimal response to this regimen, the patient was commenced on secukinumab; an IL-17 inhibitor. To our knowledge, this is the first case of the successful use of secukinumab for the treatment of immunotherapy-induced psoriasis. More importantly, immunotherapy with pembrolizumab was continued successfully with the co-administration of secukinumab without complications or the recurrence of non-small cell lung cancer (NSCLC).
Collapse
Affiliation(s)
- Elio P Monsour
- Internal Medicine, University of Central Florida / Ocala Regional Medical Center, Ocala, USA
| | - Joshua Pothen
- Internal Medicine, General Medical Education, Ocala Regional Medical Center, Ocala, USA
| | - Rama Balaraman
- Hematology and Oncology, Florida Cancer Affiliates / Ocala Oncology, Ocala, USA
| |
Collapse
|
4
|
Say M, Boralévi F, Lenormand C, Bursztejn AC, Estève E, Phan A, Bourrat E, Lacour JP, Richard MA, Acher A, Jullien D, Beneton N, Descamps V, Bodemer C, Lagaude M, Chiaverini C, Mahé E. Clinical and Therapeutic Aspects of Linear Psoriasis: A Study of 30 Cases. Am J Clin Dermatol 2018; 19:609-615. [PMID: 29594973 DOI: 10.1007/s40257-018-0354-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Psoriasis affects 2-4% of the population, with the most common clinical type being plaque psoriasis. The linear form of psoriasis is very rare. The literature on linear psoriasis (LP) consists of only case reports, and data are few. OBJECTIVE This study aimed to better understand LP in a large-scale study. PATIENTS AND METHODS We retrospectively retrieved the medical records from 14 French medical centers of patients newly diagnosed clinically with LP, with or without the support of histology, between 1 February and 31 July 2015. For each case, we assessed the clinical features, treatments and treatment efficacy. RESULTS In total, 30 cases of LP (mean age 26.8 years, 13 males) were reported. Mean age at onset of LP was 20.0 years, with 18 developing LP in childhood. Ten patients had a family history of psoriasis, and two had psoriatic arthritis. A total of 19 cases were linear at onset, with concomitant classical psoriasis; these were termed "superimposed" LP. The remaining 11 cases were not associated with classical psoriasis and were termed "isolated" LP. In four of the superimposed cases, LP developed when the patient was receiving systemic treatment: methotrexate (n = 2), etanercept (n = 1) or infliximab (n = 1). Topical steroids were effective in 76% of cases in which they were used, and systemic treatment was effective in < 66%. Treatments were less effective in LP than in classical psoriasis. DISCUSSION We identified a wide range of LP, with two profiles: isolated LP and superimposed LP. Topical treatment usually evoked clinical response, with relative resistance to systemic therapy. Methotrexate and anti-tumor necrosis factor (TNF)-α therapies can possibly unmask LP.
Collapse
Affiliation(s)
- Matthieu Say
- Service de Dermatologie, Hôpital Victor Dupouy, 69 rue du Lieutenant-Colonel Prud'hon, 95100, Argenteuil, France
| | - Franck Boralévi
- Unité de Dermatologie Pédiatrique, Hôpital Pellegrin-Enfants, Bordeaux, France
| | - Cédric Lenormand
- Service de Dermatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | | | - Eric Estève
- Service de Dermatologie, Centre Hospitalier Régional d'Orléans, Orléans, France
| | - Alice Phan
- Service de Pédiatrie, Hôpital Femme-Mère-Enfant, Bron, France
| | - Emmanuelle Bourrat
- Service de Pédiatrie Générale, Hôpital Robert Debré, Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | - Marie-Aleth Richard
- Service de Dermatologie, UMR 911 Inserm CRO2, Hôpital Timone, Assistance publique des Hôpitaux de Marseille, Centre de recherche en oncologie biologique et onco-pharmacologie, Université Aix-Marseille, Marseille, France
| | - Aurélie Acher
- Service de Dermatologie, Centre Hospitalier Universitaire de Caen, Université de Caen Basse-Normandie, UFR de Médecine, Caen, France
| | - Denis Jullien
- Service de Dermatologie, Hôpital Edouard Herriot, University Claude Bernard Lyon-1, Lyon, France
| | - Nathalie Beneton
- Service de Dermatologie, Centre Hospitalier du Mans, Le Mans, France
| | - Vincent Descamps
- Service de Dermatologie, Centre Hospitalier Universitaire Bichat-Claude Bernard, Assitance Publique-Hôpitaux de Paris, Paris 7 Diderot University, Paris, France
| | - Christine Bodemer
- Service de Dermatologie, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes Sorbonne Paris Cité, Paris, France
| | - Marion Lagaude
- Service de Dermatologie, Centre Hospitalier Universitaire de Caen, Université de Caen Basse-Normandie, UFR de Médecine, Caen, France
| | | | - Emmanuel Mahé
- Service de Dermatologie, Hôpital Victor Dupouy, 69 rue du Lieutenant-Colonel Prud'hon, 95100, Argenteuil, France.
| |
Collapse
|
5
|
Abstract
Evolution has yielded multiple complex and complementary mechanisms to detect environmental danger and protect tissues from damage. The nervous system rapidly processes information and coordinates complex defense behaviors, and the immune system eliminates diverse threats by virtue of mobile, specialized cell populations. The two systems are tightly integrated, cooperating in local and systemic reflexes that restore homeostasis in response to tissue injury and infection. They further share a broad common language of cytokines, growth factors, and neuropeptides that enables bidirectional communication. However, this reciprocal cross talk permits amplification of maladaptive feedforward inflammatory loops that contribute to the development of allergy, autoimmunity, itch, and pain. Appreciating the immune and nervous systems as a holistic, coordinated defense system provides both new insights into inflammation and exciting opportunities for managing acute and chronic inflammatory diseases.
Collapse
Affiliation(s)
- Sébastien Talbot
- F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts 02115; .,Department of Neurobiology, Harvard Medical School, Boston, Massachusetts 02115
| | - Simmie L Foster
- F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts 02115; .,Department of Neurobiology, Harvard Medical School, Boston, Massachusetts 02115
| | - Clifford J Woolf
- F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts 02115; .,Department of Neurobiology, Harvard Medical School, Boston, Massachusetts 02115
| |
Collapse
|